Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 50, 2014, Pages 17995-18000

  Stachnik, Agnes ^a   Yuen, Tony ^a   Iqbal, Jameel ^a   Sgobba, Miriam ^b   Gupta, Yogesh ^a   Lu, Ping ^a   Colaianni, Graziana ^a,c   Ji, Yaoting ^a,d   Zhu, Ling Ling ^a,d   Kim, Se Min ^a   Li, Jianhua ^a   Liu, Peng ^a   Izadmehr, Sudeh ^a   Sangodkar, Jaya ^a   Scherer, Thomas ^a   Mujtaba, Shiraz ^a   Galsky, Matthew ^a   Gomez, Jorge ^a   Epstein, Solomon ^a   Buettner, Christoph ^a   Bian, Zhuan ^d   Zallone, Alberta ^c   Aggarwal, Aneel K ^a   Haider, Shozeb ^b   New, Maria I ^a   Sun, Li ^a   Narla, Goutham ^a,e   Zaidi, Mone ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BARI   (Italy)

^d Wuhan University   (China)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer prevention; Cancer therapy; Drug repurposing

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CYCLIN B1; CYCLIN D1; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MINODRONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID; EGFR PROTEIN, HUMAN; PROTEIN BINDING; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ALPHA HELIX; ANIMAL EXPERIMENT; ANISOTROPY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER RESISTANCE; CELL VIABILITY; COLON CANCER; COMPUTER MODEL; DRUG PROTEIN BINDING; DRUG REPOSITIONING; GENE MUTATION; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN CLEAVAGE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; PROCEDURES; SIGNAL TRANSDUCTION; TUNEL ASSAY; WESTERN BLOTTING;

MUS; PYRONIA TITHONUS;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DIPHOSPHONATES; DRUG REPOSITIONING; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TUMOR STEM CELL ASSAY;

EID: 84919363339     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1421422111     Document Type: Article

References (22)

1. Russell RG (2011) Bisphosphonates: The first 40 years. Bone 49(1):2-19.
2. Wilson C, Holen I, Coleman RE (2012) Seed, soil and secreted hormones: Potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 38(7):877-889.
3. Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104(14):1059-1067.
4. Yuen T, et al. (2014) Bisphosphonates inactivate human EGFRs to exert antitumor actions. Proc Natl Acad Sci USA 111:17989-17994.
5. Gnant M, et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7):679-691.
6. Coleman RE, et al. (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365(15):1396-1405.
7. Gnant M, et al. (2011) Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res 71(24, Suppl):S1-S2.
8. Coleman R, et al. (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann Oncol 24(2):398-405.
9. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG (2012) Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register Based Cohort Study. Osteoporos Int 23(11):2693-2701.
10. Rennert G, Pinchev M, Rennert HS, Gruber SB (2011) Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 29(9):1146-1150.
11. Sendur MA, et al. (2012) Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. Med Oncol 29(4):2601-2605.
12. Ding L, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069-1075.
13. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358(11):1160-1174.
14. Nishino M, et al. (2011) Imaging of lung cancer in the era of molecular medicine. Acad Radiol 18(4):424-436.
15. Sequist LV, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26.
16. Yun CH, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105(6):2070-2075.
17. Chang JW, et al. (2009) Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. Cancer Lett 278(1):17-26.
18. Krasinskas AM (2011) EGFR signaling in colorectal carcinoma. Pathol Res Int 2011:932932.
19. Romond EH, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673-1684.
20. Di Salvatore M, et al. (2011) Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 44(2):139-146.
21. Sangodkar J, et al. (2012) Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest 122(7):2637-2651.
22. Hemmi H, et al. (2012) Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein. J Immunol 188(3):1147-1155.